[Phase II clinical study of LC9018 on carcinomatous peritonitis of gastric cancer. Subgroup for Carcinomatous Peritonitis, Cooperative, Study Group of LC9018].

Using patients with carcinomatous peritonitis caused by gastric cancer, we conducted a Phase II clinical study of LC 9018 by administering the agent alone or in combination with mitomycin C (MMC). Out of 29 patients enrolled, 12 were treated with LC 9018 alone and 17 others with LC 9018 + MMC. Of these, 15 cases were found completely evaluable. The response rate for 15 complete cases against carcinomatous peritonitis was 60.0% (3/5) for the group treated with LC9018 alone and 70.0% (7/10) with LC9018 + MMC. Of the 27 eligible patients, the ascites could be controlled in 58.3% (7/12) for those treated with LC9018 alone and 60.0% (9/15) for those with LC9018 + MMC, with tumor cells being eliminated in 50.0% (6/12) and 60.0% (9/15), respectively. Major adverse reactions included fever, nausea/vomiting, abdominal pain and increases in GOT and GPT. These findings suggest that LC9018 might be a useful therapeutic agent against carcinomatous peritonitis of gastric cancer whether used alone or in combination with MMC.
AuthorsT Okamura, Y Maehara, K Sugimachi
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 16 Issue 6 Pg. 2257-62 (Jun 1989) ISSN: 0385-0684 [Print] JAPAN
PMID2660750 (Publication Type: Case Reports, Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Adjuvants, Immunologic
  • LC 9018
  • Mitomycins
  • Adjuvants, Immunologic (adverse effects, therapeutic use)
  • Adult
  • Aged
  • Ascites (pathology, therapy)
  • Combined Modality Therapy
  • Drug Evaluation
  • Female
  • Fever (etiology)
  • Humans
  • Japan
  • Lactobacillus casei
  • Male
  • Middle Aged
  • Mitomycins (therapeutic use)
  • Multicenter Studies as Topic
  • Peritonitis (etiology, therapy)
  • Remission Induction
  • Stomach Neoplasms (complications, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: